Nonalcoholic fatty liver disease study
Protocol: SITE00000084
Full Title
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)
This study enrolls adults with nonalcoholic steatohepatitis (NASH). The purpose of this study is to learn about how much a medication called tirzepatide can help people with this condition.

You will be in this study for about a year and a half. You will take the study medication for 1 year and will have study visits and blood draws during while you are in the study. During the study you will take either different amounts of the investigational drug or a placebo. A placebo looks exactly like the investigational drug but does not have active medication in it. You will be randomly selected to be in a group, like picking a number from a hat. The chance that you will get any one of the study treatments is 1 in 4. Neither you or the study doctor will know which group you are in. The study visits take place in the Clinical and Translational Research Center, 875 Ellicott St. Buffalo, NY 14203 and/or Kaleida Health facilities.
Compensation: Yes
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Adults ages 18-80.
Overweight or obese.
Diagnosis of NASH by liver biopsy in the past 6 months.
Have fibrosis stage 2 or 3.
Age Group: Adults
Principal Investigator: AJAY CHAUDHURI
Chelsea Cowan
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact